Consensus extraction protocol development for infection in Alzheimer's disease

This project is a collaborative research initiative calling for the establishment of a consensus protocol to identify and evaluate microbial infections that may contribute to cognitive impairment and dementias, including Alzheimer’s disease. Motivated by accumulating evidence that the Aβ peptide—long recognized as a hallmark protein in Alzheimer’s-affected brains—also participates in the immune response to pathogens, the researchers argue that infection can act as a primary cause of certain dementias and that downstream failure or chronic activation of this immune response can lead to sustained inflammation, neurodegeneration, and cell death.

The work is framed as both a synthesis of recent scientific findings and a practical roadmap for the scientific community to move from controversy to consensus about the role of microbes in neuroinflammation and neurodegeneration. The core aim is to develop and validate a standardized, reproducible detection protocol—the Alzheimer’s Pathobiome Initiative—that will allow researchers and clinicians to characterize the brain pathobiome reliably in living patients. To accomplish this, the team emphasizes urgent needs for interdisciplinary collaboration among neuropathologists, neurologists, microbiologists, molecular biologists, bioinformatics experts, and others. The proposed consensus process would identify which tissues and biosamples best represent the brain microbiome and which extraction and analytic methods—or combinations of methods—are most effective for detecting microbial nucleic acids in those samples. Recognizing the diversity of potential biosamples, the group catalogs options such as cerebrospinal fluid, blood draws, and nasal brush sampling, while noting that establishing standardized protocols for extracting nucleic acids from tissue or fluid is a major task.

Once consensus on sampling and extraction methods is achieved, the authors propose a pilot study applying the consensus detection protocol to patients across varying stages of dementia and Alzheimer’s disease. The ultimate objective of such testing would be to determine whether appropriate antimicrobial therapeutic paths can be identified for patients with infection-associated neurocognitive decline, with the long-term aim of arresting or reversing disease progression where microbes are implicated. The call for consensus is presented not as an endpoint but as a catalyst for global scientific interaction and consolidation of effort.

The initiative’s proposed steps—agreement on representative biosamples, standardization of nucleic acid extraction methods, validation of detection approaches, and pilot clinical testing—are designed to create reproducible laboratory results that can support clinical decision-making. By advocating for standardized approaches to diagnosing infections in patients with neurocognitive change, this project seeks to clarify which infections exist in affected brains and to provide a roadmap toward interventions that treat dementias based on infectious contributions. The project positions consensus protocol development as foundational to transforming an emerging, sometimes controversial, body of evidence into actionable, collaborative science that could ultimately reshape diagnostic and therapeutic strategies for Alzheimer’s disease.